Aberrant expression of the c-myc gene results from nonrandom chromosomal translocations involving the transcriptionally active antigen receptor gene loci, in particular lymphocytic leukemias and lymphomas, and is believed to contribute to the etiology of these neoplasms. In addition to its expression in abnormal lymphocytes, increased accumulation of c-myc mRNA occurs rapidly in normal B-and T-lymphocytes after stimulation with appropriate mitogens. The mechanisms that mediate these mitogen-induced elevations in c-myc mRNA levels, however, have not been determined for normal B and T cells. By using enriched populations of B-and T-lymphocytes obtained from freshly isolated human tonsils and stimulated with Staphylococcus-A or with phytohemagglutinin, respectively, we observed marked elevations (20-40-fold) in the steady state levels of accumulated c-myc messenger RNA (mRNA) within 1 h of exposure of cells to mitogens; modest increases (three-to fivefold) in the relative rate of transcription of the c-myc gene through protein synthesisindependent (cycloheximide-insensitive) mechanisms; and rapid rates of degradation of mature c-myc mRNAs through protein synthesis-dependent (cycloheximide-sensitive) mechanisms. These findings corroborate previous studies in other cell types and provide evidence for both transcriptional and posttranscriptional control of c-myc proto-oncogene expression in normal human lymphocytes. and lymphomas, and is believed to contribute to the etiology of these neoplasms. In addition to its expression in abnormal lymphocytes, increased accumulation of c-myc mRNA occurs rapidly in normal B-and T-lymphocytes after stimulation with appropriate mitogens. The mechanisms that mediate these mitogeninduced elevations in c-myc mRNA levels, however, have not been determined for normal B and T cells. By using enriched populations of B-and T-lymphocytes obtained from freshly isolated human tonsils and stimulated with Staphylococcus-A or with phytohemagglutinin, respectively, we observed marked elevations (20-40-fold) in the steady state levels of accumulated cmyc messenger RNA (mRNA) within I h of exposure of cells to mitogens; modest increases (three-to fivefold) in the relative rate of transcription of the c-myc gene through protein synthesisindependent (cycloheximide-insensitive) mechanisms; and rapid rates of degradation of mature c-myc mRNAs through protein synthesis-dependent (cycloheximide-sensitive) mechanisms. These findings corroborate previous studies in other cell types and provide evidence for both transcriptional and posttranscriptional control of c-myc proto-oncogene expression in normal human lymphocytes.
Introduction
The c-myc proto-oncogene encodes a 65-68-kd (kilodalton) phosphoprotein that resides in the nucleus of cells and, at least in vitro, binds DNA with high affinity (1) . High levels of constitutive expression ofthis gene have been observed in lymphoid neoplasms as a result of chromosomal translocations involving immunoglobulin gene loci in human and murine B cell tumors (Burkitt's lymphoma, murine plasmacytomas) (2) ; translocations involving T cell antigen receptor genes in occasional cases of acute T-lymphocytic leukemia in humans (3); and retrovirusmediated promoter/enhancer insertion mechanisms in avian leukosis virus-induced B cell tumors and in Moloney murine leukemia virus-induced murine T cell neoplasms (4, 5) . More rarely, increased expression of the c-myc proto-oncogene can occur in nonlymphoid neoplasms because ofgene amplification, as in HL60 acute promonomyelocytic human cells, in a polyoma virus-transformed osteosarcoma and in some Abelson leukemia virus-transformed murine National Institutes of Health (NIH) 3T3 fibroblast cell lines (6) (7) (8) . In the majority of cases, no alterations in the coding sequences of the c-myc gene have been detected, thus providing at least correlative evidence that deregulated production ofthe normal c-myc gene product contributes to the etiology of these neoplasms.
In addition to constitutive expression in particular leukemias and lymphomas, transient and inducible expression of the cmyc proto-oncogene occurs in several types of normal cells when stimulated to proliferate. Typically, levels of c-myc messenger RNA (mRNA) rise rapidly, peaking within 1-3 h, then gradually decline, and return to baseline 1-2 d later in normal cells. This time course of c-myc gene expression has been observed in Blymphocytes stimulated with lipopolysaccharide (LPS) or antiimmunoglobulin antibodies (9, 10) , resting T-lymphocytes stimulated with mitogenic lectins (9, 11), activated T cells treated with interleukin 2 (IL-2, T cell growth factor) (12) , quiescent fibroblasts induced to proliferate with serum (9) , and hepatocytes after partial hepatectomy (13) . These findings have suggested that expression ofthe c-myc gene plays a role in normal cellular proliferation. Indeed, gene transfer experiments in fibroblasts (NIH 3T3 cells) have shown that c-myc can reduce the requirement for platelet-derived growth factor for proliferation (14) , and microinjection studies have similarly shown that c-myc protein can render these cells "competent" to respond to progression factors present in platelet-poor plasma (15) . The c-myc protooncogene product thus may serve some important function during early stages of normal cellular growth. However, a role for c-myc during later phases ofthe cell cycle has also been suggested by a recent report demonstrating that microinjection of c-myc protein can modulate DNA polymerase activity and is required for DNA synthesis in isolated nuclei (16) .
Given the above evidence that c-myc may participate in the regulation of normal and abnormal cellular growth, it is important to understand the mechanisms that control the expression of this proto-oncogene. Despite extensive investigations in a variety of normal and neoplastic cells, the fundamental aspects ofthe regulation ofc-myc gene expression remain undetermined for normal T- RNA blot analysis. Relative levels of accumulated mRNAs were measured by Northern blot analysis exactly as described (1 1, 12) . Briefly, total cellular RNA was isolated from lymphocytes by a guanidium isothiocyanate method with cesium chloride modification, and equal amounts of RNA (10 Mg/lane) were size-fractionated by electrophoresis through formaldehyde-containing 1% agarose gels. Before transfer to nylon membranes (Gene Screen Plus, DuPont Co., Diagnostic & BioResearch Systems, Wilmington, DE), ethiudium-stained gels were visualized under ultraviolet illumination to determine the positions of 28S and 18S ribosomal RNA (rRNA) bands, to assess integrity of RNA, and to verify equal amounts of RNA were loaded. Membranes were then hybridized under high-stringency conditions (50% formamide, I M NaCI; 42°C) with various 32P-labeled DNA probes (-109 cpm/ug) including pRYC7.4 (human c-myc), He7 control probe (pHe7), and pAl (chicken fl-actin) (19) (20) (21) . After 24 h, membranes were washed as described previously (final washes in 15 mM NaCl, 1.5 mM sodium citrate, and 0.1% sodium dodecyl sulfate [SDS] at 50°C) and exposed to Kodak XAR film at -70°C with intensifying screens. Relative intensities of bands on autoradiograms were quantified by scanning densitometry using an ultrascan (LKB Instruments, Inc., Gaithersburg, MD).
Nuclear transcription assays. Measurements of relative rates of cmyc gene transcription were conducted by nuclear transcription ("run off") assays essentially as described (22). After stimulation oflymphocytes for various times, nuclei were isolated by incubating cells for 5 min on ice in lysing solution (0.3 M sucrose, 60 mM KC1, 15 mM Hepes [pH 1. Abbreviations used in this paper: CHX, cycloheximide; PHA-P, phytohemagglutinin-P; pHe7, 32P-labeled He7 control probe; SAC, Staphylococcus aureus Cowan strain I; UTP, uridine triphosphate. Comparison of the time course of c-myc mRNA accumulation with that of DNA synthesis (Fig. 1, bottom Further evidence that labile proteins contribute to the regulation of c-myc mRNA levels in normal B and T cells is provided by the data in Fig. 2 (Fig. 2 C) .
The data in Fig. 2 indicate that c-myc mRNA undergoes rapid turnover in mitogen-stimulated lymphocytes and provide presumptive evidence that CHX augments levels of c-myc mRNA, at least in part, by diminishing its rate of degradation. Though CHX may have some nonspecific stabilizing effects on mRNA t1/2 (see actin data on Fig. 2 C and [26] ), this seems an inadequate explanation for the marked increase in the t1/2 of c-myc mRNA in CHX-treated cells.
Analysis ofc-myc gene transcription in mitogen-stimulated B-and T-lymphocytes. Because steady state levels ofaccumulated mRNA reflect the net of RNA synthesis and RNA degradation, we next examined directly relative rates ofc-myc gene transcription with the use of nuclear (run off) transcription assays (22). For these experiments (Fig. 3) , nuclei were isolated from B and T cells after treatment with mitogens, CHX, or various combinations of these reagents, and nascent transcripts were elongated in vitro in the presence of [32P]TTP. The resultant 32p-transcripts were then hybridized to nitrocellulose filters onto which various plasmid DNAs (pRYC7.4 [human c-myc], pHe7, Al [28S rRNA]) has been immobilized by using a slot-blot apparatus. Fig. 3 shows transcription data derived from B and T cflls stimulated for 0, 1, 6, or 24 h with appropriate mitogens before isolation of nuclei. As shown, transcription of the c-myc gene was barely detectable in resting lymphocytes. After treatment with mitogens, relative rates of c-myc transcription increased approximately threefold, becoming maximal between 1 and 6 h and declining toward baseline levels by 24 h. Unlike experiments that measured steady state levels ofmRNA (Fig. 2) , CHX had little effect on the rate ofc-myc gene transcription in mitogenstimulated lymphocytes (Fig. 3) Here we have investigated the fundamental mechanisms that regulate the levels of c-myc mRNA in normal human B-and T-lymphocytes. Given that steady state levels of c-myc mRNA rose 20-40-fold in mitogen-stimulated lymphocytes (Fig. 1) , whereas relative rates ofc-myc transcription increased only about threefold (Fig. 3) , our findings corroborate previous reports sug- 2' TIME (HRS) [19]), pHe7 (positive control [20] ), pBR322 (negative control [23] ), and Al (28S rRNA [24] ). In some cases, slots were reordered for clarity of presentation. In preliminary experiments (not shown), adding 2 ug/ml a-amanitin to transcription reactions, specifically impaired transcription of genes for c-myc and He7 but not for 28S rRNA. Scanning densitometric quantification of nuclear transcription data are shown (right) for B cells (top) and T cells (bottom) stimulated for 0, 1, 6, or 24 h with appropriate mitogens. Data are expressed as the ratio of c-myc to He7 after subtraction of background hybridization (pBR322) and normalization to the 28S rRNA signal.
gesting that c-myc mRNA accumulation is regulated primarily through posttranscriptional mechanisms in normal cells (27) (28) (29) (30) (31) . It should be noted, however, that our results with primary cultured human B-and T-lymphocytes differ from several previous investigations that used long-term cultured cells. In those studies, relatively high rates of c-myc transcription were present in resting cells and little or no increase above the baseline rate of transcription was detected in BALB/c mouse 3T3 fibroblast cells treated with serum, platelet-derived growth factor, or PMA (28); in CCL39 Chinese hamster lung fibroblast cells stimulated with thrombin and insulin (31) ; and in MSB-l-transformed avian T-lymphocytes released from density arrest (29) . In contrast to these studies in fibroblasts and transformed T cells, our transcription data are similar to those showing an increase in cmyc transcription in primary cultures of mitogen-stimulated human T-lymphocytes (32) and in long-term cultured CT6 cells, a cloned murine T cells, stimulated with IL-2 (33 .4) , encoding only the second and third exons of the c-myc gene (19). Though a variety of c-myc probes were used in the above mentioned studies oflong-term cultured cells (27) (28) (29) (30) (31) , in at least one of these reports (31) the same pRYC7.4 probe was employed. Thus, differences in the probes selected for transcription studies cannot fully account for the discrepancy between findings in normal lymphocytes and in other types of cells.
Our investigations of the effects of CHX on relative rates of c-myc transcription in normal human B and T cells demonstrated that synthesis ofnew proteins is not required for mitogen-induced increases in the transcription of this proto-oncogene (see Fig.  3 ). These findings (Fig. 3) are consistent with reports in other types of cells (28, 29, 31, 32) and indicate that the activity of preexisting regulators of c-myc gene transcription in normal lymphocytes is controlled through protein synthesis-independent mechanisms.
In contrast to its actions on c-myc transcription, CHX markedly decreased the turnover of mature c-myc mRNAs in B-and T-lymphocytes (see Fig. 2 ). Steady state levels of accumulated c-myc mRNA therefore appear to be regulated, at least in part, through posttranscriptional mechanisms in normal lymphocytes. Previous investigations in a variety of cells have suggested an important role for posttranscriptional mechanisms in the control of c-myc mRNA levels (27) (28) (29) (30) (31) . For example, induction ofdifferentiation of Daudi cells (Burkitt's lymphoma cell line) with gamma interferon produces decreases in the levels of accumulated c-myc mRNA that are associated with diminished c-myc mRNA stability without a change in the rate of c-myc transcription (30) . With regard to investigations in Daudi cells, normal lymphocytes, and other cells, however, it should be noted that regulation at additional posttranscriptional steps, such as processing, cannot be excluded.
Though the mechanisms that influence the degradation of c-myc mRNA remain to be elucidated fully, the ability of CHX to augment levels of c-myc mRNA in resting lymphocytes (Fig'  2 A) suggests that c-myc degradation is regulated by a labile protein that is constitutively present in lymphocytes, rather than by a protein whose synthesis is induced after stimulation with mitogens. Use of preexisting proteins to regulate c-myc expression would be expected to allow for more rapid alterations in the levels of c-myc mRNA than if new protein synthesis were required.
In summary, our findings here demonstrate that levels of c-myc mRNA are regulated similarly in normal B-and T-lymphocytes and that both transcriptional and posttranscriptional mechanisms are involved. Though many details remain unknown, these studies begin to define the molecular events that control the expression of the c-myc proto-oncogene in normal human lymphocytes.
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